Compare · BSX vs DRTS
BSX vs DRTS
Side-by-side comparison of Boston Scientific Corporation (BSX) and Alpha Tau Medical Ltd. (DRTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and DRTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $65.44B, about 54.9x DRTS ($1.19B).
- Over the past year, BSX is down 57.5% and DRTS is up 349.8% - DRTS leads by 407.4 points.
- DRTS has been more active in the news (12 items in the past 4 weeks vs 2 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 7 for DRTS).
- Company
- Boston Scientific Corporation
- Alpha Tau Medical Ltd.
- Price
- $44.02-1.32%
- $13.54+13.78%
- Market cap
- $65.44B
- $1.19B
- 1M return
- -6.16%
- +44.66%
- 1Y return
- -57.53%
- +349.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 2
- 12
- Recent ratings
- 25
- 7
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Latest DRTS
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
- Chief Financial Officer Levy Raphi sold $31,782 worth of Ordinary Shares (2,270 units at $14.00) and exercised 2,270 units of Ordinary Shares at a strike of $2.98 (SEC Form 4)
- Chief Financial Officer Levy Raphi exercised 17,873 units of Ordinary Shares at a strike of $2.98 and sold $232,397 worth of Ordinary Shares (17,873 units at $13.00) (SEC Form 4)
- Chief Financial Officer Levy Raphi exercised 2,127 units of Ordinary Shares at a strike of $2.98 and sold $27,691 worth of Ordinary Shares (2,127 units at $13.02) (SEC Form 4)
- Chief Financial Officer Levy Raphi sold $240,044 worth of Ordinary Shares (20,000 units at $12.00), decreasing direct ownership by 18% to 90,180 units (SEC Form 4)
- Chief Financial Officer Levy Raphi sold $220,004 worth of Ordinary Shares (20,000 units at $11.00), decreasing direct ownership by 15% to 110,180 units (SEC Form 4)
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
- Chief Financial Officer Levy Raphi sold $167,051 worth of Ordinary Shares (17,500 units at $9.55), decreasing direct ownership by 12% to 130,180 units (SEC Form 4)